Raine Visiting Professor Lecture – 4 April 2018

Professor John Crispino

Northwestern University, USA

will present a Raine Lecture entitled:

Myeloproliferative neoplasms: from bench to bedside

on Wednesday 4 April 2018 from 12 – 1 pm

at the McCusker Auditorium, Harry Perkins Institute of Medical Research

All welcome

Professor John Crispino, PhD, MBA, is the Robert I. Lurie, MD and Lora S. Lurie Professor of Medicine at Northwestern University, the Vice Chief of Research in the Division of Hematology/Oncology, and the Associate Director of Education and Training for the Robert H. Lurie Comprehensive Cancer Center. He received his PhD from MIT for research on the mechanisms of RNA splicing performed in the laboratory of Dr. Phillip Sharp, Nobel Laureate in Physiology or Medicine. He then performed post-doctoral haematology research at Harvard Medical School and Children’s Hospital of Boston with Dr. Stuart Orkin before moving to Chicago in 2000, and obtaining an MBA at Northwestern University in 2011.

Professor Crispino’s laboratory were the first to identify specific genetic mutations that are associated with leukaemia in children with Down syndrome and are at the forefront of research on the relationship between trisomy 21 and abnormal blood cell development. His current research includes the role of transcription factors in the specification and maturation of blood cells, characterising genetic defects in Myeloproliferative Neoplasms and Acute Myeloid Leukaemia, and developing novel, targeted therapies. He has authored over 100 publications, with recent papers in Nature Medicine, Cell, Cell Stem Cell, Molecular Cell, Journal of Clinical Investigation, and Blood. Prof Crispino was named the 2011 Illinois Leukemia Researcher of the year by the Pamela B. Katten Memorial Leukemia Research Foundation. He is on the editorial boards of Leukemia and Blood Cancer Journal and reviews grants for the NIH, the Leukemia and Lymphoma Society, and the American Society of Hematology. He is currently the Scientific Advisor to the Myeloproliferative Neoplasm Research Foundation and on the medical advisory board of the Rally Foundation for Childhood Cancer Research. He also collaborates with Forma Therapeutics, Astra Zeneca, and Amgen, and has been a consultant to Geron Corporation and Janssen Pharmaceuticals.

University Host:
Professor Wendy Erber
School of Biomedical Sciences
University of Western Australia
Telephone: 6457 2325
Email: wendy.erber@uwa.edu.au